Blog

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Aug 8 • 5 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. AGN Neuro is the world’s first…

Mind Cure Announces Closing of LNG Energy’s Subscription Receipt Financing

Aug 8 • 2 min read

Mind Cure Health Inc. (CSE: MCUR / OTCQB: MCURF / FRA: 6MH) is pleased to announce that in connection with the Company’s previously announced reverse takeover transaction (the “Proposed Transaction“) with LNG Holdings Inc. (formerly known as LNG Energy Group Inc.) (“LNG Energy“), LNG Energy closed its private placement of 44,577,350 subscription receipts of LNG…

Braxia Scientific Financial Report Analysis

Aug 7 • 3 min read

The release of quarterly financial reports over the past few weeks is providing some much-needed insight into the state of the industry. It is becoming apparent which companies are rising to the top and which are struggling to stay afloat. The recent release of Braxia Scientific’s financial statement raises some questions about its ability to…

Psychedelics and SSRIs: What the Science Says

Aug 4 • 6 min read

Psychedelic science is in its infancy stage, so there is a lot that is still unknown. One of these unknowns is the safety and efficacy of taking a psychedelic medicine while on a Selective Serotonin Reuptake Inhibitor (SSRI). This is a question that is often discussed. There has always been concern and interest about the…

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

Aug 4 • 3 min read

Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has initiated dosing in Cohort 6, the final cohort of its Phase 2 study evaluating CYB003, an investigational deuterated analog of psilocybin for the potential treatment of major depressive…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538